Skip to main content

Table 1 Characteristics of patients with periprosthetic joint infections caused by methicillin-resistant Staphylococcus undergoing 2-stage revision arthroplasties

From: Methicillin-resistant Staphylococcal periprosthetic joint infections can be effectively controlled by systemic and local daptomycin

No.

Sex

Age

Surgical procedures

CCI

Pathogen

Antibiotic regimen (bone cement g/systemic mg/kg)

Use daptomycin in bone cement at reimplantation (Y/N)

FU (months)

Outcome

1

M

65

DAIR for TKA

4

MRSA

DAP 4/DAP 6

Y

26

Infection controlled

2

M

51

THA

4

MRSA

DAP 4 + CEF 4/DAP 6

N

32

Infection controlled

3

M

72

DAIR for revision TKA

5

MRSE

DAP 4/DAP 6

Y

43

Infection controlled

4

M

53

Revision THA

2

MRCoNS

DAP 4 + CEF 4/DAP 6

N

42

Infection controlled

5

F

60

TKA

3

MRSA

DAP 4 + CEF 4/DAP 6

Y

38

Infection controlled

6

F

80

DAIR for TKA

5

MRSE

DAP 4/DAP 6

Y

26

Infection controlled

7

M

66

DAIR for THA

3

MRCoNS

DAP 4/DAP 6

N

51

Infection controlled

8

M

44

DAIR for THA

2

MRSE

DAP 4/DAP 6

N

42

Infection controlled

9

M

74

DAIR for TKA

4

MRSE

DAP 4/DAP 6

Y

25

Infection controlled

10

M

45

DAIR for THA

3

MRSE

DAP 4/DAP 6

N

26

Infection controlled

11

M

51

DAIR for THA

4

MRSA

DAP 4/DAP 6

Y

44

Infection controlled

12

F

67

TKA

5

MRSA

DAP 4 + CEF 4/DAP 6

Y

32

Infection controlled

13

F

86

TKA

5

MRSA

DAP 4 + CEF 4/DAP 6

Y

37

Infection controlled

14

M

51

DAIR for THA

5

MRSA

DAP 4/DAP 6

N

40

Infection controlled

15

F

86

TKA

5

MRSA

DAP 4 + CEF 4/DAP 6

Y

30

Infection controlled

16

F

81

THA

3

MRSA

DAP 4 + CEF 4/DAP 6

Y

32

Infection controlled

17

M

81

DAIR for revision TKA

5

MRSE

DAP 4/DAP 6

Y

30

Infection controlled

18

M

51

DAIR for revision THA

4

MRCoNS

DAP 4/DAP 6

N

31

Infection controlled

19

M

50

DAIR for THA

2

MRSE

DAP 4/DAP 6

N

27

Infection controlled

20

M

87

TKA

6

MRSA

DAP 4 + CEF 4/DAP 6

Y

24

Infection controlled

21

M

38

DAIR for THA

2

MRSE

DAP 4/DAP 6

N

30

Infection controlled

22

M

78

DAIR for revision THA

6

MRCoNS

DAP 4/DAP 6

Y

33

Infection controlled

  1. DAIR debridement, antibiotics, irrigation and prosthesis retention, CCI Charlson comorbidity index, DM diabetes mellitus, HTN hypertension, CVA cerebral vascular accident, TKA total knee arthroplasty, LC liver cirrhosis, RA rheumatoid arthritis, THA total hip arthroplasty, CAD coronary artery disease, BMI body mass index, HBV hepatic B virus, HCV hepatic C virus, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, DAP daptomycin, CEF ceftazidime, MRSA methicillin-resistant Staphylococcus aureus, MRCoNS methicillin-resistant coagulase-negative Staphylococci, MRSE methicillin-resistant Staphylococcus epidermis, FU follow-up